Otolin-1 as a biomarker for the evaluation of the effectiveness of betahistine treatment for benign paroxysmal positional vertigo

Basit Öğe Kaydı
dc.contributor.authorKaraer, Isil Cakmak
dc.contributor.authorUrhan, Ayca
dc.contributor.authorAkalin, Yahya
dc.date.accessioned2025-10-24T18:09:15Z
dc.date.available2025-10-24T18:09:15Z
dc.date.issued2023
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractObjectiveBenign paroxysmal positional vertigo (BPPV) is the most common vertigo disorder. Betahistine is the most commonly used drug in the treatment of vertigo, however its effect on the inner ear is not fully known. Otolin-1 is an inner ear-specific glycoprotein that can be identified in peripheral blood. The aim of the study was to determine the effect of treatment of betahistine for BPPV on serum otolin-1 levels.MethodsThirty (30) patients with BPPV and 30 healthy controls were enrolled in the study. Serum otolin-1 levels were measured before and 14 days after perioral (po) betahistine treatment in the BPPV group, whereas otolin-1 level was examined once in controls. The efficacy of treatment was evaluated with Dizziness Handicap Index (DHI) and Visual Analog Scale (VAS) in the BPPV group.ResultsOtolin-1 levels were statistically significantly higher in patients with BPPV than controls. In the BPPV group, serum otolin-1 level was found to be statistically significantly lower after betahistine treatment. There was a statistically significantly difference between pre-treatment and posttreatment groups regarding to both DHI and VAS scores.ConclusionSerum otolin-1 can be used as a biomarker in monitoring the effectiveness of treatment of BPPV with betahistine as well as diagnosis of BPPV.
dc.identifier.doi10.1080/21695717.2023.2213957
dc.identifier.endpage322
dc.identifier.issn2169-5717
dc.identifier.issn2169-5725
dc.identifier.issue4
dc.identifier.startpage318
dc.identifier.urihttps://doi.org/10.1080/21695717.2023.2213957
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3548
dc.identifier.volume21
dc.identifier.wosWOS:001038073800001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofHearing Balance And Communication
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectBenign paroxysmal positional vertigo; betahistine; otolin-1
dc.titleOtolin-1 as a biomarker for the evaluation of the effectiveness of betahistine treatment for benign paroxysmal positional vertigo
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu